业绩总结 - 2024年预计的特许权使用费收入为9000万至9500万美元，较2023年增长16%[9] - 核心调整后稀释每股收益（EPS）预计为4.25至4.75美元，较2023年增长17%[9] - 2024年总收入预计为1.3亿至1.42亿美元，其中Captisol收入为2500万至2700万美元，合同收入为1500万至2000万美元[9] - 2024年第一季度，Kyprolis的销售额为3.76亿美元，预计2024年全球销售总额超过15亿美元[28] - Filspari在2024年第一季度的销售额为1980万美元，预计将成为Ligand最大的特许权收入来源[28] 用户数据与市场展望 - Ligand的特许权收入预计将超过20%的年复合增长率（CAGR）[8] - 2024年，Captisol平台的收入预计为2500万至2700万美元，反映出其在行业中的持续需求[31] 新产品与研发 - 预计Soticlestat将在2024年9月发布顶线数据，2025年第一季度进行监管申请[29] 投资与财务状况 - 2023年，Ligand审查了超过300项投资，签署了45份保密协议，完成了5项投资[26] - Ligand的现金和投资总额为3.11亿美元，截至2024年3月31日[5]

业绩总结 - 2024年总收入指导为1.6亿至1.65亿美元，较2023年增长24%[30] - 2024年预计特许权使用费收入为1.05亿至1.08亿美元，较2023年增长27%[30] - 2024年合同收入预计为2800万美元，较2023年增长47%[30] - 2024年调整后的每股收益（EPS）预计为5.50至5.70美元，较2023年增长38%[30] - 2024年现金运营利润预计为1.14亿至1.19亿美元，较2023年增长38%[30] - 2025年总收入预期为1.8亿至2亿美元，较2024年增长17%[33] - 预计2025年特许权使用费收入将增长30%[35] - 2025年调整后的核心每股收益预期在6.00至6.25美元之间[37] 用户数据 - 2024年Captisol销售预计为2700万至2900万美元[30] - 2025年Captisol销售预计增长33%[36] - Zelsuvmi的峰值净销售机会预计将超过2亿美元[110] 未来展望 - 预计2024年至2029年特许权使用费收入年复合增长率（CAGR）为22%[24] - Ligand预计2024年至2029年间，特许权使用费将以超过20%的年复合增长率增长[115] 新产品和新技术研发 - Pelthos的Zelsuvmi是FDA批准的首个家庭治疗产品，针对每年约600万名美国儿童的传染性皮肤病[110] - Captisol技术已被用于16个FDA批准的产品中，涵盖15个FDA和1个日本市场[99] - NITRICIL平台已在1个FDA批准的产品中得到应用，未来有望扩展到其他皮肤病[112] 市场扩张和并购 - 2025年Qarziba的收购预计将每年增加1美元的调整后每股收益[32] 负面信息 - Ligand在2018年和2023年进行了项目融资，并计划在2024年进行可转换债券融资[90] 其他新策略和有价值的信息 - 截至2024年第三季度，现金和投资总额为2.2亿美元[6] - 2024年已部署投资总额为1.92亿美元，涉及8个不同的投资项目[21] - 2024年运营支出预计为3500万美元，较2023年减少10%[30] - Ligand的Captisol平台预计将继续产生显著的特许权使用费收入，且运营费用极低[105]

This is my ninth Ligand (NASDAQ: LGND ) article, following my most recent 11/2024 "Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies." In Dozens Of Therapies , IWriting under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ~5 years of focused research ...

The event will include presentations from Ligand's senior management team highlighting the company's strategy, investment activity, royalty portfolio, and long-term financial outlook. A live webcast of the event will be accessible through Ligand's Investor Relations website at investor.ligand.com. A detailed agenda, including dial-in information, will be provided closer to the event. About Ligand Pharmaceuticals Investors: Melanie Herman investors@ligand.com (858) 550-7761 Media: Kellie Walsh media@ligand.c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Pe ...

Ligand Pharmaceuticals (LGND) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Melanie Herman - Executive Director - Investor Relations and FP&ATodd Davis - CEORichard Baxter - SVP, Investment OperationsTavo Espinoza - CFOLauren Hay - Vice President - Strategic Planning & Investment AnalyticsAnnabel Samimy - Managing Director Conference Call Participants Douglas Miehm - AnalystMatt Hewitt - Senior Research AnalystTrevor Allred - Biotech AnalystJohn Vandermosten - Senior Analyst Operator T ...

Ligand Pharmaceuticals (LGND) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ligeland First Quarter twenty twenty five Earnings. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Thank you. I would now like to turn the call over to Melanie Herman, Executive Director ...

Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.25 1 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 8, 2025 – Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss this announcement ...

First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.251 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported fi ...

JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright Royalty Company Conference (Virtual). Management will participate in a fireside chat on May 13, 2025 at 3:30 p.m. ET and be available for one-on-one meetings.RBC Capital Markets Global Healthcare Conference (New York). Management will participate in a fireside chat on May 20, 2025 at ...